Daniel J Deer
Overview
Explore the profile of Daniel J Deer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
1059
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Woolsey C, Cross R, Chu V, Prasad A, Agans K, Borisevich V, et al.
Sci Adv
. 2025 Mar;
11(11):eadw0659.
PMID: 40085692
Obeldesivir (ODV; GS-5245) is an orally administered ester prodrug of the parent nucleoside GS-441524 that has broad spectrum antiviral activity inhibiting viral RNA-dependent RNA polymerases. We recently showed that ODV...
2.
Cross R, Woolsey C, Prasad A, Borisevich V, Agans K, Deer D, et al.
Nat Med
. 2025 Jan;
PMID: 39805309
The recent outbreak of Marburg virus (MARV) in Rwanda underscores the need for effective countermeasures against this highly fatal pathogen, with case fatality rates reaching 90%. Currently, no vaccines or...
3.
Zeitlin L, Cross R, Woolsey C, West B, Borisevich V, Agans K, et al.
Sci Transl Med
. 2024 Apr;
16(741):eadl2055.
PMID: 38569014
No licensed vaccines or therapies exist for patients infected with Nipah virus (NiV), although an experimental human monoclonal antibody (mAb) cross-reactive to the NiV and Hendra virus (HeV) G glycoprotein,...
4.
Cross R, Woolsey C, Chu V, Babusis D, Bannister R, Vermillion M, et al.
Science
. 2024 Mar;
383(6688):eadk6176.
PMID: 38484056
Obeldesivir (ODV, GS-5245) is an orally administered prodrug of the parent nucleoside of remdesivir (RDV) and is presently in phase 3 trials for COVID-19 treatment. In this work, we show...
5.
Cross R, Fenton K, Woolsey C, Prasad A, Borisevich V, Agans K, et al.
Cell Rep Med
. 2024 Jan;
5(2):101392.
PMID: 38280377
Lassa fever (LF) is an acute viral illness that causes thousands of deaths annually in West Africa. There are currently no Lassa virus (LASV) vaccines or antivirals approved for human...
6.
Woolsey C, Cross R, Prasad A, Agans K, Borisevich V, Deer D, et al.
Emerg Microbes Infect
. 2024 Jan;
13(1):2301061.
PMID: 38164768
Lassa virus (LASV) is a World Health Organization (WHO) priority pathogen that causes high morbidity and mortality. Recently, we showed that a combination of three broadly neutralizing human monoclonal antibodies...
7.
To A, Wong T, Ball A, Lieberman M, Yalley-Ogunro J, Cabus M, et al.
Vaccine
. 2023 Dec;
42(3):598-607.
PMID: 38158300
Although two vaccines for Zaire ebolavirus (EBOV) have been licensed and deployed successfully to combat recurring outbreaks of Ebolavirus Disease in West Africa, there are no vaccines for two other...
8.
Cross R, Wiethoff C, Brown-Augsburger P, Berens S, Blackbourne J, Liu L, et al.
Pathogens
. 2023 Dec;
12(12).
PMID: 38133292
As part of the non-clinical safety package characterizing bamlanivimab (SARS-CoV-2 neutralizing monoclonal antibody), the risk profile for antibody-dependent enhancement of infection (ADE) was evaluated in vitro and in an African...
9.
Cross R, Heinrich M, Fenton K, Borisevich V, Agans K, Prasad A, et al.
Proc Natl Acad Sci U S A
. 2023 Aug;
120(34):e2304876120.
PMID: 37590417
There are no approved treatments for Lassa fever (LF), which is responsible for thousands of deaths each year in West Africa. A major challenge in developing effective medical countermeasures against...
10.
Abelson D, Barajas J, Stuart L, Kim D, Marimuthu A, Hu C, et al.
J Infect Dis
. 2023 Jul;
228(Suppl 7):S701-S711.
PMID: 37474248
Marburg virus (MARV) causes a hemorrhagic fever disease in human and nonhuman primates with high levels of morbidity and mortality. Concerns about weaponization of aerosolized MARV have spurred the development...